Prediction of relapse in hyperthyroid Graves' disease

Area of Science:

• Endocrinology
• Immunology

Background:

• Graves' disease is an autoimmune disorder causing hyperthyroidism.
• Carbimazole is a common treatment for hyperthyroidism.
• Relapse after carbimazole treatment is frequent.

Purpose of the Study:

• To determine predictors of relapse after carbimazole treatment for Graves' disease.
• To assess the utility of HLA-DRw3 status and thyrotropin-receptor antibody levels in predicting outcomes.

Main Methods:

• Prospective study of 65 patients with hyperthyroid Graves' disease treated with carbimazole.
• Analysis of HLA-DRw3 status and thyrotropin-receptor antibody levels at drug withdrawal.
• Correlation of these markers with relapse or remission rates within one year.

Main Results:

• 63% of patients (41/65) experienced hyperthyroidism recurrence within one year of stopping carbimazole.
• Combined analysis of HLA-DRw3 status and thyrotropin-receptor antibody levels predicted relapse or remission in 95% (62/65) of patients.

Conclusions:

• Hyperthyroidism recurrence is common after carbimazole treatment for Graves' disease.
• HLA-DRw3 status and thyrotropin-receptor antibody levels are strong predictors of treatment outcome.
• These markers can aid in personalized management strategies for Graves' disease.